1. Exact Sciences reported strong Q4 revenue growth, but missed EPS due to an $838M impairment charge from the Thrive acquisition. 2. Despite the negative market reaction, Exact's core business shows momentum with strong demand for Cologuard and a solid cash position of $1.04B. 3. The company has ambitious 2025 revenue guidance and expects new product launches to drive growth, aiming for sustained profitability and long-term value.